Du är här

2016-02-04

Bavarian Nordic A/S: Bavarian Nordic Enters Research Collaboration to Develop MRSA Vaccine

COPENHAGEN, Denmark, February 4, 2016
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has
entered into a joint collaboration with Evaxion Biotech, a Danish
biotechnology company, and Technical University of Denmark (DTU), for the
development of an MVA-BN-based vaccine against MRSA
(Methicillin-resistantStaphylococcus aureus
) using Evaxion's computer-based technology to discover novel antigens. The
same approach could potentially be used to target any other bacteria that
have developed resistance to antibiotics.

Based on promising efficacy results demonstrated by Evaxion in preclinical
models, Bavarian Nordic intends to engineer and produce a recombinant
MVA-BN-based vaccine candidate, which will be investigated in additional
preclinical studies by DTU. If proven safe and efficacious, human trials
could occur in 2019.

The project has received initial funding from the Innovation Fund Denmark in
the amount of DKK 17 million (USD 2.5 million*), which in part will fund
Bavarian Nordic's production of MVA-BN-based MRSA vaccine candidates.

MRSA is associated with deaths and a high rate of hospitalization, and thus
carries a high burden in terms of public health care costs. MRSA remains a
major challenge in the healthcare sector due to high infection risk during
treatment and surgery of patients, in particular those with weak immune
systems. There is no MRSA vaccine available and therefore an effective MRSA
vaccine would reduce mortality and infection rates.

"We are pleased to join this collaboration and take part in the efforts to
develop an effective vaccine that may eventually help improve public health
and reduce mortality" said Paul Chaplin, Ph.D. and Chief Executive Officer of
Bavarian Nordic. "In addition, this collaboration provides an opportunity to
investigate MVA-BN in new indications, which yet again broadens the scope of
our vaccine platform technology."

About MVA-BN®

MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and
patented vaccine platform technology of Bavarian Nordic, originally developed
through a successful public-private partnership with the U.S. Government.
MVA-BN is a robust and adaptable platform with the potential to address a
wide variety of infectious diseases and cancers.

In addition to developing MVA-BN as a safer smallpox vaccine (approved in the
EU and Canada) essential to protecting the immune-compromised population, and
through a partnership with Janssen as an Ebola vaccine, Bavarian Nordic has
conducted more than a dozen preclinical and clinical studies of recombinant
MVA-BN-based vaccines. More than 7,600 individuals, nearly 1,000 of whom are
immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing
the platform displays high immunogenicity and a favorable safety profile.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies
and vaccines for infectious diseases, based on the Company's live virus
vaccine platform. Through long-standing collaborations, including a
collaboration with the U.S. government, Bavarian Nordic has developed a
portfolio of vaccines for infectious diseases, including the non-replicating
smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the
United States and other governments. The vaccine is approved in the European
Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are developing an Ebola vaccine regimen, which has been
fast-tracked, with the backing of worldwide health authorities. Additionally,
in collaboration with the National Cancer Institute, Bavarian Nordic has
developed a portfolio of active cancer immunotherapies, including PROSTVAC®,
which is currently in Phase 3 clinical development for the treatment of
advanced prostate cancer. The company has partnered with Bristol-Myers Squibb
for the potential commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control,
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information, and
in particular statements with respect to the goals and prospects of the
collaboration between Bavarian Nordic and Evaxion Biotech and the potential
development of a vaccine against MRSA. All such forward-looking statements
are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.

Contacts

Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

* USD/DKK = 6.80

20160204en
http://hugin.info/100065/R/1983575/726974.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

HUG#1983575

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.